Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Roivant Sciences (ROIV) · oqro.io/stocks/ROIV · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Have Roivant Sciences insiders bought shares recently?
No open-market purchase by an insider of Roivant Sciences was filed in the last 90 days. The latest on record was on Sep 18, 2025.
How often do Roivant Sciences insiders buy and sell shares?
Since 2022, Roivant Sciences insiders reported 4 open-market purchases and 326 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2025.
Who is selling Roivant Sciences stock?
In the last 90 days, 8 insiders of Roivant Sciences (ROIV) reported 44 open-market sales worth $231M in total on SEC Form 4. The largest seller by value was Keith S Manchester, with $53.5M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade ROIV?
Yes. Members of Congress disclosed 3 trades in Roivant Sciences (ROIV) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Rep. Lisa C. McClain (MI09).
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+90.7% (+$18.39) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $20.27 on Nov 20, 2025 to $38.66 on Nov 20, 2026 (+90.7%). Disclosed in this range: 96 insider trades, 33 pre-arranged insider sales, 0 Congress trades, and 28 13F position changes for 3 quarters ending in it.
$15$20$25$30$35$45$38.66
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 129 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biotechnology company based in London, United Kingdom.
Last 12 months
+90.7%
S&P 500 +5.7% over the same dates
Market value
$28.1B
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 45.5M shares sold short (6.3% of shares outstanding), +12.9% vs the previous count, 6.1 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Latest results: quarter ending Sep 30, 2026
Revenue
$35.1M
+2135.6% vs the same quarter a year earlier
Free cash flow, last 12 months
−$33.3M
This quarter $594M, a year earlier −$194M
Net debt
—
Debt —, cash $1.64B, at Sep 30, 2026
Net income, last 12 months
−$344M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 9, 2026.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for Roivant Sciences over the 12 months to Nov 20, 2026: 3 executive contributions.
Insider buying and selling since 2022
Insiders of Roivant Sciences reported 4 open-market purchases and 326 sales since 2022; purchases in 2 different years, most recently 2025.
Year
Bought
Sold
2026
—
$687M100×100 trades
2025
$50K1×1 trade
$534M80×80 trades
2024
—
$152M23×23 trades
2023
—
$998M74×74 trades
2022
$20.2M3×3 trades
$97.9M49×49 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Since Nov 17, 2025, ROIV is up 88.4% and the index fund is up 9.7%: 79 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much ROIV moves
A usual day
±1.5%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
3.9%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−7.6%Aug 28, 2026
Largest one-day rise
+22.1%Feb 6, 2026
Deepest fall of the year
−20.2%From the close of Sep 9, 2026 to Oct 13, 2026.
Days of 5% or more
13Out of 252 sessions, in either direction.
Beta 1.2(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
Last 30 days
Written by software from the filings listed below · Nov 19, 2026
Insiders. In the 30 days to Nov 19, 2026, insiders of Roivant Sciences filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 31 open-market sales (about $202M, in 8 filings, by 5 people). One Form 4 can list many transactions. In the 30 days before that, they filed 0 open-market purchases (about $0, in 0 filings) and 3 open-market sales (about $7.96M, in 2 filings). (Roivant Sciences on OQRO)
Contracts, lobbying and filings. FINRA short interest for ROIV on the settlement date of Oct 30, 2026 was 45,513,591 shares (+12.93% on the previous report), about 6.07 days of average volume. In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Farallon Capital Management, L.L.C. (increased, 4,634,000 shares); Rubric Capital Management LP (increased, 1,000,000 shares); the largest that shrank: Voleon Capital Management LP (sold out); MUFG Securities EMEA plc (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Roivant Sciences filed a Form 8-K on Nov 9, 2026 (Item 2.02) that OQRO classes as: reported its results. Press coverage listed by Finnhub: "Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum" (SeekingAlpha, Nov 11, 2026).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 30 days to Nov 19, 2026, insiders of Roivant Sciences filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 31 open-market sales (about $202M, in 8 filings, by 5 people). One Form 4 can list many transactions.
In the 30 days before that, they filed 0 open-market purchases (about $0, in 0 filings) and 3 open-market sales (about $7.96M, in 2 filings).
The largest sale: Daniel Allen Gold, Director, about $21.6M, filed Nov 18, 2026.
Contracts, lobbying and filings
FINRA short interest for ROIV on the settlement date of Oct 30, 2026 was 45,513,591 shares (+12.93% on the previous report), about 6.07 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Farallon Capital Management, L.L.C. (increased, 4,634,000 shares); Rubric Capital Management LP (increased, 1,000,000 shares); the largest that shrank: Voleon Capital Management LP (sold out); MUFG Securities EMEA plc (sold out). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2026, the company's proxy statement reported total compensation of $3.1M for its principal executive officer, and an average of $38.3M for the other named executive officers.
Company reports, price and press
Roivant Sciences filed a Form 8-K on Nov 9, 2026 (Item 2.02) that OQRO classes as: reported its results.
Press coverage listed by Finnhub: "Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum" (SeekingAlpha, Nov 11, 2026).
Press coverage listed by Finnhub: "Roivant Sciences Q2 Earnings Call Highlights" (Yahoo, Nov 9, 2026).
Press coverage listed by Finnhub: "Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update" (Yahoo, Nov 9, 2026).
ROIV closed at $38.73 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $34.70 to $38.73, a change of +11.6%.
Things to keep in mind
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Roivant Sciences filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 141 open-market sales (about $1.04B, in 51 filings, by 12 people). One Form 4 can list many transactions. In the 12 months before that, they filed 1 open-market purchase (about $50K, in 1 filing) and 47 open-market sales (about $205M, in 26 filings). (Roivant Sciences on OQRO)
Congress. Members of Congress filed 3 disclosures on Roivant Sciences in the 12 months to Nov 19, 2026: 1 purchase and 2 sales, by 1 member. In the 12 months before that: 1 disclosure. The largest range: Rep. Lisa C. McClain (MI09), $1,001 to $15,000, filed Nov 21, 2025.
Funds and stakes. Fund 13F filings recorded in the 12 months show 13 new or larger positions and 15 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. FINRA short interest for ROIV on the settlement date of Oct 30, 2026 was 45,513,591 shares (+12.93% on the previous report), about 6.07 days of average volume. In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Farallon Capital Management, L.L.C. (increased, 4,634,000 shares); Rubric Capital Management LP (increased, 1,000,000 shares); the largest that shrank: Voleon Capital Management LP (sold out); MUFG Securities EMEA plc (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Roivant Sciences filed a Form 8-K on Nov 9, 2026 (Item 2.02) that OQRO classes as: reported its results. Roivant Sciences filed a Form 8-K on Aug 6, 2026 (Item 2.02) that OQRO classes as: reported its results.
Who holds it. 495 funds reported a stake in Roivant Sciences in their 13F for Q2 2026. The largest by value: FMR LLC (14.4% of the value reported), BlackRock, Inc. (8.6% of the value reported), MORGAN STANLEY (7.5% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Roivant Sciences filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 141 open-market sales (about $1.04B, in 51 filings, by 12 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 1 open-market purchase (about $50K, in 1 filing) and 47 open-market sales (about $205M, in 26 filings).
The largest sale: Ramaswamy Vivek, 10% owner, about $43.4M, filed Dec 16, 2025.
Congress
Members of Congress filed 3 disclosures on Roivant Sciences in the 12 months to Nov 19, 2026: 1 purchase and 2 sales, by 1 member. In the 12 months before that: 1 disclosure.
The largest range: Rep. Lisa C. McClain (MI09), $1,001 to $15,000, filed Nov 21, 2025.
Funds and stakes
Fund 13F filings recorded in the 12 months show 13 new or larger positions and 15 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
FINRA short interest for ROIV on the settlement date of Oct 30, 2026 was 45,513,591 shares (+12.93% on the previous report), about 6.07 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Farallon Capital Management, L.L.C. (increased, 4,634,000 shares); Rubric Capital Management LP (increased, 1,000,000 shares); the largest that shrank: Voleon Capital Management LP (sold out); MUFG Securities EMEA plc (sold out). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2026, the company's proxy statement reported total compensation of $3.1M for its principal executive officer, and an average of $38.3M for the other named executive officers.
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Roivant Sciences filed a Form 8-K on Nov 9, 2026 (Item 2.02) that OQRO classes as: reported its results.
Roivant Sciences filed a Form 8-K on Aug 6, 2026 (Item 2.02) that OQRO classes as: reported its results.
Roivant Sciences filed a Form 8-K on May 20, 2026 (Item 2.02) that OQRO classes as: reported its results.
Press coverage listed by Finnhub: "Keith Manchester Sells $54M Of Roivant Sciences Stock After Sharp Run-Up" (Benzinga, Nov 19, 2026).
Press coverage listed by Finnhub: "Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum" (SeekingAlpha, Nov 11, 2026).
Press coverage listed by Finnhub: "Roivant Sciences Q2 Earnings Call Highlights" (Yahoo, Nov 9, 2026).
ROIV closed at $38.73 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $34.70 to $38.73, a change of +11.6%.
Who holds it
495 funds reported a stake in Roivant Sciences in their 13F for Q2 2026. The largest by value: FMR LLC (14.4% of the value reported), BlackRock, Inc. (8.6% of the value reported), MORGAN STANLEY (7.5% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
4 certified in FY2026 Q3, vs 1 a year earlier. 4 positions in total, median offered wage $188K a year.
CHIEF BUSINESS OFFICER · 1Chief of Staff · 1Founding Engineer, Roivant Health · 1Senior Associate, Investments · 1
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Off-exchange trading: 43.4% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (26.2% on ATS, 17.2% with other brokers), above its 26-week average of 41.1%. Weeks of Oct 5 to Oct 30, 2026.
Week of May 4ATSOther off-exchangeFull height = all shares tradedWeek of Oct 26
Largest ATS: INTELLIGENT CROSS LLC (12.0%), UBS ATS (10.7%), SIGMA X2 (9.3%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 10,000 words.
From “Overview”, in the company's words
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 currently under review at the FDA for the treatment of dermatomyositis and also in late stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease.
What the section covers (34 headings)
Overview
Components of Results of Operations
Revenue
Cost of revenues
Research and development expenses
Acquired in-process research and development expenses
General and administrative expenses
Gain on sale of Telavant net assets
Gain on litigation settlement
Gain on deconsolidation of subsidiaries
Interest income
Income tax expense
Income (loss) from discontinued operations, net of tax
Net loss attributable to noncontrolling interests
And 20 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed May 20, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Risk factors in the annual report
Latest annual report filed May 20, 2026, compared with the one filed May 29, 2025. Read the filing
New risk factors in the latest annual report (6 headings)
Immunovant relies on the HanAll Agreement to provide the rights to the core intellectual property relating to IMVT-1402 and batoclimab. Any termination or loss of significant rights under the HanAll Agreement could adversely affect Immunovant’s development or commercialization of IMVT-1402.
Changes in tariffs and other governmental trade policies could negatively affect our business and results of operations.
Legislation targeting biotechnology companies with ties to certain foreign adversaries, including the BIOSECURE Act, could materially adversely affect our business, supply chain and results of operations.
The biopharmaceutical industry is subject to extensive regulatory obligations and policies that may be subject to significant and abrupt change, including due to judicial challenges, election cycles and resulting regulatory updates and changes in policy priorities.
Cross-border transfers of personal data and compliance with international data protection regulations, including the GDPR, create legal and operational risks for our business.
Compliance with FDA electronic records and data integrity requirements creates cybersecurity-adjacent regulatory risk that could adversely affect our business.
No longer listed (5 headings from the year before)
FDA approval for a product candidate in the United States does not guarantee that we will be able to or that we will make efforts to obtain approval for or commercialize our product candidates in any other jurisdiction, which would limit our ability to realize the product candidate’s full market potential.
The markets in which our healthcare technology and computational drug discovery Vants participate are competitive, and if we do not compete effectively, our business and operating results could be adversely affected.
We may not hold a controlling stake in certain of our Vant affiliates and thus may not be able to direct our business or the development of our product candidates.
We have incurred and will continue to incur increased costs as a result of operating as a public company and our management has devoted and will continue to devote a substantial amount of time to new compliance initiatives.
Our largest shareholders own a significant percentage of our common shares and are able to exert significant control over matters subject to shareholder approval.
Legal proceedings (Item 3)
From time to time, we may become involved in legal or regulatory proceedings arising in the ordinary course of our business. We do not currently, however, expect any such legal proceedings to have a material adverse effect on our business, operating results or financial condition. However, depending on the nature and timing of a given dispute, an unfavorable resolution could materially affect our current or future results of operations or cash flows.
Source: SEC EDGAR, Form 10-K filed May 20, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.